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Resveratrol is a pleiotropic phytochemical belonging to the stilbene family. Though it 
is only significantly present in grape products, a huge amount of preclinical studies 
investigated its anticancer properties in a plethora of cellular and animal models. 
Molecular mechanisms of resveratrol involved signaling pathways related to extracellular 
growth factors and receptor tyrosine kinases; formation of multiprotein complexes and 
cell metabolism; cell proliferation and genome instability; cytoplasmic tyrosine kinase 
signaling (cytokine, integrin, and developmental pathways); signal transduction by the 
transforming growth factor-β super-family; apoptosis and inflammation; and immune 
surveillance and hormone signaling. Resveratrol also showed a promising role to 
counteract multidrug resistance: in adjuvant therapy, associated with 5-fluoruracyl and 
cisplatin, resveratrol had additive and/or synergistic effects increasing the chemosensi-
tization of cancer cells. Resveratrol, by acting on diverse mechanisms simultaneously, 
has been emphasized as a promising, multi-target, anticancer agent, relevant in both 
cancer prevention and treatment.
Keywords: stilbenes, cancer chemoprevention, polyphenols, nutritional therapy, multi-target agents, bioavailability
iNTRODUCTiON
Stilbenes are secondary metabolites produced by plants in response to stressful conditions, particu-
larly fungal infection and UV radiation. Resveratrol, naturally occurring in some plant foods, but 
especially contained in grapes and red wine, is the most investigated and well-known member of 
this class of compounds. Being already in use in clinical settings because of the documented cancer 
and chemopreventive activities (1), it recently displayed a high impact in oncology, identifiable by 
checking the number of clinical trials, registered and ongoing, on international databases, such 
as US and EU clinical trial registers (Table  1). Moreover, epidemiological data support as the 
consumption of resveratrol is associated with the inhibition of several chronic disorders, including 
cancer (2). In particular, resveratrol-rich food intake has been reported to produce a significant 
decrease in the incidence of skin and breast cancers as well as in the progression of lung adeno-
carcinoma (3, 4).
This narrative review aims to summarize the current body of evidence, within the last 10 years, 
about the anticancer and chemoprevenive molecular mechanisms of resveratrol. In October 2015, 
we consulted PubMed and EMBASE databases for extensive search of articles on this topic. Multiple 
molecular targets, related to the different carcinogenesis pathways, were analyzed focusing on pre-
clinical evidence, necessary both to screen molecules up to support in vitro and, then, in vivo efficacy 
and to provide clues on their molecular basis of activity (5). Particular emphasis was provided to the 
TABLe 1 | Clinical trials on resveratrol and cancer recorded on US and 
eU registers.
Title (identifier number) Condition(s)
www.clinicaltrials.gov
Resveratrol for Patients with Colon Cancer (NCT00256334) Colon cancer
Resveratrol in Treating Patients with Colorectal Cancer that 
Can Be Removed by Surgery (NCT00433576)
Adenocarcinoma 
of the colon/
rectum
A Biological Study of Resveratrol’s Effects on Notch-1 
Signaling in Subjects with Low-Grade Gastrointestinal 
Tumors (NCT01476592)
Neuroendocrine 
tumor
Phase I Biomarker Study of Dietary Grape-Derived 
Low Dose Resveratrol for Colon Cancer Prevention 
(NCT00578396)
Colon cancer
Resveratrol and Human Hepatocyte Function in Cancer 
(NCT02261844)
Liver cancer
A Clinical Study to Assess the Safety, Pharmacokinetics, 
and Pharmacodynamics of SRT501 in Subjects with 
Colorectal Cancer and Hepatic Metastases (NCT00920803)
Colon-rectal 
cancer
UMCC 2003-064 Resveratrol in Preventing Cancer in 
Healthy Participants (NCT00098969)
Unspecified adult 
solid tumors
A Clinical Study to Assess the Safety and Activity of 
SRT501 Alone or in Combination with Bortezomib in 
Patients with Multiple Myeloma (NCT00920556)
Multiple myeloma
www.clinicaltrialsregister.eu
Prostate Phytochemical & PUFA Intervention (EudraCT 
Number: 2006-006679-18)
Localized prostate 
cancer
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ability of resveratrol in reducing the risk of multidrug resistance 
(MDR), via multiple cellular targets involved in carcinogenesis 
and chemo/radioresistance, which mediate its synergy with the 
chemotherapeutics (6). In this direction, a more  punctual 
 comprehension of resveratrol mechanism(s) of action can pro-
mote the development of novel, multi-target cancer therapies, in 
order to improve drug efficacy and MDR elusion.
CHeMiSTRY AND BiOAvAiLABiLiTY OF 
ReSveRATROL
Resveratrol (trans-3,4′,5-trihydroxystilbene) is a non-flavonoid 
polyphenol belonging to the stilbenes. In plants, the molecule 
exists in two isomers, trans-resveratrol and cis-resveratrol, and 
their glucosides, trans-piceid and cis-piceid. The unconjugated 
(aglycone) trans-isomer is the most studied, in vitro, at concen-
trations largely exceeding those found in the human circulatory 
system after dietary intake. A recent study suggested that to 
accomplish the same concentrations used in vitro, 111 glasses of 
wine need to be consumed daily to reach the Bench Mark Dose 
(7). Moreover, resveratrol possesses a low bioavailability: it is 
rapidly metabolized in intestine and liver by phase II enzymes, 
and the end products of this metabolism are mainly glucuronide 
and sulfate derivatives (8) (Figure 1).
In particular, physiological levels of resveratrol-3-O- 
glucuronide, resveratrol-4′-O-glucuronide, and resveratrol-3-O-
sulfate have been recently tested and showed inefficacy against 
Jurkat T leukemia cells (9). None of these metabolites arrested or 
impaired cell proliferation; the unique evidence was the induction 
of mitochondrial membrane depolarization by resveratrol-3-O-
sulfate, devoid of any consequence on cell death (9).
Abbreviations: α-MSH, alpha-melanocyte-stimulation hormone; 5-FLU, 
5-fluoruracyl; AIF, apoptosis-inducing factor; AP, activator protein; APO-1 or APT, 
apoptosis antigen 1; Atg, autophagy-related genes; Bak, Bcl-2-antagonist/killer-1; 
Bax, Bcl-2-associated X protein; Bcl, B-cell lymphoma; Bcl-xL, B cell lymphoma-
extra large; (BH)3, Bcl-2 homolog; BRCA, BReast and ovarian CAncer growth-
suppressor protein; CASP, caspases; CAT, catalase; CD95, cluster of differentiation 
95; CDKs, cyclin-dependent kinases; cGMP/PKG, cyclic guanosine monophos-
phate/cGMP-dependent protein kinase; Cmpd1, (E)-4-(3,5-dimethoxystyryl)
phenyl acetate; COX-2, selective cyclooxygenase-2; CRC, colon carcinoma 
cancer; CREB, cAMP response element binding; CSCs, cancer stem cells; DAG, 
diacylglycerol; DD, death domain; DHEA, dehydroepiandrosterone; DHEAS, 
dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; DP, dimerization 
partner; EGF, epidermal growth factor; EGF-R, epidermal growth factor receptor; 
Egr, early growth response; EMT, epithelial–mesenchymal transition; ERs, estrogen 
receptors; ERK, extracellular-signal-regulated kinases; SNAI1 or Snail, family zinc 
finger 1; FADD, Fas-associated protein with death domain; FasL, Fas ligand; FasR, 
Fas receptor; FOXO, forkhead box O; GADD, growth arrest and DNA damage; 
GL1, glioblastoma; GTP, guanosine 5′-triphosphate; H2AX, H2A histone family, 
member X; Hh, Hedgehog; hTERT, human telomerase reverse transcriptase; HtrA2, 
high temperature requirement serine protease A2; HUVECs, human umbilical 
vein endothelial cells; IAPs, baculoviral inhibitor of apoptosis proteins; ICAM, 
intercellular adhesion molecule; IκBα, inhibitor of nuclear factor kappa B (NF-κB) 
α; NF-κB inhibitor α; Ihh, Indian hedgehog homolog; IKK, kinase subunit; IL, inter-
leukin; INF, interferon; JNK, c-Jun N-terminal kinases; lncRNAs, long non-coding 
RNAs; M12, 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene; M6, 3,3′,4,4′-tetrahydroxy-
trans-stilbene; M8, 3,4,4′,5-tetrahydroxy-trans-stilbene; MAPK, mitogen-activated 
protein kinase; MCP, monocyte chemoattractant protein; MDR, multidrug 
resistance; MEK, mitogen-activated protein kinase kinase; miRNAs, microRNAs; 
MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; NAMPT, 
nicotinamide phosphoribosyltransferase; NEMO, NF-κB essential modifier; 
NF-κB, nuclear factor kappa-B; NO, nitric oxide; NOS, NO synthase; NSAIDs, non-
steroidal inflammatory drugs; Omi, protein HtrA2; u-PA, plasminogen activator; 
PARP-1, poly(ADP ribose); Pax, paired box; PDK, phosphoinositide-dependent 
kinase; PGC1α, proliferator-activated receptor gamma coactivator 1-alpha; PGE2, 
prostaglandin E2; PI3K, phosphatidylinositol 3-kinase; PIAS3, protein inhibitor of 
activated STAT3; PKB or AKT, protein kinase B; PKC, protein kinase C; PPAR, 
peroxisome proliferator-activated receptor; PSA, prostate-specific antigen; Ptch, 
patched; PTEN, phosphatase and tensin homolog; PUMA, p53 upregulated 
modulator of apoptosis; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma; 
ROS, reactive oxygen species; RPTKs, receptor protein tyrosine kinases; pRb, 
retinoblastoma protein; Smac, second mitochondria-derived activator of caspase; 
Smac/DIABLO, second mitochondria-derived activator of caspase/direct inhibitor 
of apoptosis-binding protein with low pI; siRNA, small interference RNA; SIRT, 
sirtuin; Smad, son of mothers against decapentaplegic; SMO, smoothened; STAT3, 
signal transducer and activator of transcription; SUMO, small ubiquitin-related 
modifier; SOD, superoxide dismutase; MnSOD, manganese-dependent superoxide 
dismutase; TGF-β, transforming growth factor-β; TAM, tumor-associated mac-
rophages; Tif, transcriptional intermediary factor; TNF-α, tumor necrosis factor α; 
TNFRSF6, TNF-receptor super-family member 6; TOPO, topoisomerase; TORC, 
transducer of regulated CREB; TRAIL, TNF-related apoptosis-inducing ligand; 
TTF, thyroid transcription factor; VEGF, vascular endothelial growth factor; Wnt, 
wingless integration; XIAP, X-linked inhibitor of apoptosis.
TARGeTeD MOLeCULAR PATHwAYS
Preclinical data support phytochemicals interaction with many 
molecular and biochemical targets involved in chemical carcino-
genesis, a complex three-stage process from cancer initiation 
FiGURe 1 | Metabolism of resveratrol-3-glucoside (piceid), the main metabolite of resveratrol present in plant foods, in human gastrointestinal tract; 
after piceid deconjugation, resveratrol-3-glucuronide, resveratrol-4′-glucuronide, resveratrol-3-sulfate, and resveratrol-4′-sulfate are the main 
phase ii metabolites of resveratrol aglycone.
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to promotion and progression, up to invasion and metastasis 
(Figure 2) (10). In case of resveratrol, many chemopreventive and 
chemotherapeutic mechanisms to prevent, arrest, or reverse car-
cinogenesis stages have been investigated. Following mechanisms 
shared among several phytochemicals, resveratrol can act as sup-
pressive agent on several impaired signaling pathways, acquiring 
the role of functionally pleiotropic agent, which expresses its 
activity on multiple targets in cancer cells with limited toxicity 
toward normal cells (Figure 3). Among cellular changes, the most 
important ones can be identified in accelerated transition of cells 
through cell cycle checkpoints with abnormal cell proliferation, 
genome instability, abnormal response to signals or other stimu-
lators of programed cell death, uncontrolled neoangiogenesis, 
increased oxidative stress, overproduction of growth regulatory 
hormones, and alteration in host immune responses. Further 
contribution comes from the antioxidant, anti-inflammatory 
and immunomodulatory activities, reducing damage induced 
by oxidative stress (DNA damage, protein oxidation, and lipid 
peroxidation) and increasing immune oncosurveillance (10, 
11). Resveratrol can also act as blocking agent by stopping the 
transformation of procarcinogen to carcinogen, since it inhibits 
the monooxygenase cytochrome P450 isoenzyme CYP1 A1, the 
enzyme deputed to the liver metabolism of xenobiotics (12, 13).
Along these lines, recent efforts in cancer therapeutics are 
directed against aberrant signal transduction pathways related to a 
diverse range of conditions; resveratrol appears to display multiple, 
contextual targeting activities by specific interaction with different 
biomolecules (15). Table 2 summaries the multi-target anti-cancer 
activities of resveratrol and related preclinical evidences.
extracellular Growth Factors and 
Receptor Tyrosine Kinases
Antigrowth signaling activity is among the major targets of phy-
tochemicals. Resveratrol specifically targets epidermal growth 
factor (EGF) and related receptor (EGF-R), a transmembrane 
tyrosine kinase activated by ligands, and the transforming growth 
FiGURe 2 | Carcinogenesis and cancer chemoprevention. Neoplastic process consists of three distinct, temporally ordered and linked stages: initiation, 
promotion, and progression. Chemopreventive agents are of two types: suppressing agents that inhibit the malignant transformation of initiated/preneoplastic cells 
and blocking agents that prevent the metabolic activation of procarcinogens [adapted from Ref. (14)].
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factor-beta (TGF-β). EGF-R promotes cell growth and prolif-
eration, and it is typically over-expressed in aggressive tumor 
phenotypes (16). Acting on EGF-R pathway, resveratrol and two 
of its derivatives, acetyl-resveratrol and polydatin, displayed the 
dose-dependent antigrowth effects against 3D cell aggregates of 
the EGF-R/Her-2-positive and -negative ovarian cancer cell lines, 
although via different signaling molecules (17). When tested 
on the positive ovarian cell line and at high concentrations, in 
particular, resveratrol and polydatin (but not acetyl-resveratrol) 
significantly reduced the phosphorylation of Her-2 and EGF-R, 
and decreased the expression of extracellular-signal-regulated 
kinases (ERK) and vascular endothelial growth factor (VEGF) 
(17). In agreement with these findings, Strickland and al. reported 
the inhibition of VEGF production, contextually to the amplified 
expression of p53 and matrix protein TSP1, testing resveratrol 
on a coculture of vascular endothelial and melanoma cells (18).
To better clarify the role of the molecule on the endothelial 
function and the pro- and antiangiogenic activities, the nitric oxide 
(NO) pathway was also investigated. In human umbilical vein 
endothelial cells (HUVECs), resveratrol raised NO production via 
increasing expression and activation of endothelial NO synthase 
(e-NOS), particularly acting on endogenous downstream cyclic 
guanidin monophosphate/protein kinase G (NO/cGMP/PKG) 
pathway and downstream cell-survival proteins [baculoviral 
inhibitor of apoptosis proteins (IAPs)] (19). Resveratrol, at high 
concentrations, inhibited HUVEC tube formation and cell migra-
tion and invasion, indices of neo-angiogenesis; it also suppressed 
endogenous PKG kinase activity and decreased the expression 
of four cell-survival proteins, i.e., IAP repeat-containing protein 
2 and 3 (c-IAP1 and 2), livin, and the X-linked inhibitor of 
apoptosis (XIAP), which is E3 ubiquitin protein ligase (19). At 
low concentrations, in contrast, it stimulated cell proliferation, 
protecting HUVECs against apoptosis (19).
These findings support the function of resveratrol as suppres-
sive agent able to block all carcinogenetic stages mediated by 
over-expression of growth factors and receptor tyrosine kinases. 
Acting particularly on EGF, resveratrol suppresses initiation, pro-
motion, and progression of carcinogenesis while reducing VEGF 
expression as well as promoting NOS activity; it can prevent the 
formation of more aggressive tumor phenotypes, reducing neo-
angiogenesis and the risk of metastasis and cancer-related tissue 
hypoxia.
FiGURe 3 | Mechanisms involved in the anticancer activity of resveratrol. A number of cell processes are targeted by resveratrol, by upregulating (+) or 
downregulating (−) different pathways. ROS, reactive oxygen species; COX, cyclooxygenase; NFκB, nuclear factor κB; AP-1, activator protein 1; CDKs, cyclin-
dependent kinases; BAX, B cell lymphoma-associated X; Bcl2, B cell lymphoma 2; ERs, estrogen receptors; HIF-1α, hypoxia-induced factor 1α; MMPs, matrix 
metalloproteinases.
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Formation of Multiprotein Complexes, 
Signal Transmission, and  
Cell Metabolism (Red–Ox)
Activated receptor protein tyrosine kinases (RPTKs) produce 
networks of signaling molecules, which consist of both preformed 
and rapidly associating protein complexes that transmit informa-
tion throughout the cell. Growth factor receptors can activate, 
in turn, phosphoinositide signaling, where phospholipids of 
cell membrane contribute to signal propagation via two main 
mechanisms: (i) serving as precursor of the second messengers 
diacylglycerol (DAG), phosphatidylinositol 3-kinase (PI3K), 
and Ca2+ or (ii) binding to signal proteins containing specific 
phosphoinositide-binding modules.
Among the others, protein kinase B (PKB, also named AKT), 
rat sarcoma (RAS), and rapidly accelerated fibrosarcoma (RAF) 
are three of the most important serine/threonine-specific protein 
kinases, with a pivotal regulatory role in signaling cascade. AKT 
is activated by conformational changes evoked by phospholipid 
binding, and it phosphorylates two major downstream kinases, 
i.e., phosphoinositide-dependent kinase 1 (PDK-1) and the com-
plex named transducer of regulated “cAMP response element-
binding (CREB)” (TORC)-2; the latter includes serine threonine 
kinase mammalian target of rapamycin (mTOR). AKT activation 
regulates functions pivotal for cell growth, such as protein trans-
lation, glucose uptake, and glycolysis, and controls cell survival, 
through the phosphorylation and nuclear exclusion of transcrip-
tion factors, which prevent the expression of genes, inducing cell 
death. AKT has several further targets, including the nuclear 
gene transcription mediators, e.g., forkhead box O (FOXO). 
RAS oncogenes are, instead, small guanosine 5′-triphosphate 
(GTP)-ases, which serve as master regulators of a myriad of sign-
aling cascades involved in miscellaneous cellular processes. RAS 
transmits extracellular signals to intracellular effectors pathways: 
the activation of RAF kinases requires the interaction with RAS, 
which, in turn, activates mitogen/extracellular-signal-regulated 
kinases (MEK) and extracellular-signal-regulated kinases (ERK). 
Besides the so-called RAS/RAF/MEK/ERK cascade, better 
known as mitogen-activated protein kinase (MAPK), RAS can 
also regulate the PI3K/AKT/mTOR signaling pathway.
Resveratrol has effect on the phosphatase and tensin homolog 
(PTEN)/AKT pathway, commonly deregulated in prostate can-
cer. The direct effect of resveratrol corresponds to a reduction 
in phosphorylation of AKT, as well as of mTOR and FOXO; in 
particular, the dephosphorylation of FOXO results in its trans-
location to the nucleus and further activation (20). Consistently, 
a syngenic mouse model of melanoma showed as the treatment 
with resveratrol reduced tumor volume and metastasis through-
out reduced AKT expression (21).
Therefore, these data support the specific activity of resveratrol 
in controlling the formation of multiprotein RPTKs complexes 
and related signaling pathways, i.e., AKT and mTOR, which, 
when impaired, are involved in all stages of carcinogenesis, from 
initiation to metastasis.
In addition, resveratrol directly inhibited all phases of car-
cinogenesis modulating red–ox signaling. Both antioxidant and 
TABLe 2 | Molecular mechanism of resveratrol and derivatives anticancer activity.
Target in carcinogenetic 
processes
Cancer cells Molecular pathways Reference
Extracellular growth factors 
and receptor tyrosine 
kinases
Melanoma EGF-R/EGF, TGF-β, Her-2, p53, TSP1, and VEGF (16)
Human umbilical vein endothelial cells NO/eNOS, NO/cGMP/PKG, IAP1 and 2, livin, and XIAP (17)
Ovarian carcinoma (Her-2+ and −) (18)
(19)
Formation of multiprotein 
complexes, signal 
transmission and cell 
metabolism (red–ox)
Prostate carcinoma
Melanoma
Colon carcinoma
Ovary carcinoma
T cell leukemia Jurkat
Lung adenocarcinoma (+As2O3)
PTEN/AKT, mTOR, FOXO, DNA damage leukocytic, red–ox imbalance 
(enzymatic and non-enxymatic mechanisms), SOD and CAT, DNA glycosylase I
(20)
(21)
(22)
(23)
(24)
(25)
Biological outcomes of 
growth factor signaling: cell 
proliferation and genome 
instability
Oral squamous cell carcinoma
Human epidermoid carcinoma
Anaplastic thyroid carcinoma
Colon carcinoma
Lung adenocarcinoma
Gliobastoma
Breast carcinoma
Non-melanoma skin cancer (+5-FLU)
Lung adenocarciomaa
Osteosarcoma
Colon carcinoma (+DOX)
Cell cycle arrest at G2/M and at G1/S transition, cyclin A2 and cyclin B1, cyclin 
D1, cyclin D2 and cyclin E, CDK inhibitor-cyclin-CDK machinery, WAF1/p21, 
CDK2, CDK4, and CDK6
A3 adenosine receptors, lncRNA (AK001796), TOPO2, H2AX
BRCA1, cyclin B1, pRb, and p21
TOPO2
(26)
(27)
(28)
(31)
(32)
(33)
(34)
(35)
(36, 37)
(38)
(39)
Cytoplasmic tyrosine 
kinase signaling
Cytokine signaling
Human embryonic kidney cell line
Breast carcinoma
Pancreas adenocarcinoma
Human Embryonic Kidney cell line
NF-κB, IKKα, IKK-γ, NEMO, p65, TNF-α, Ad.Egr-TNF, Egr-1 promoter, AP-1, 
AP-2 and cAMP, CREB, MMP-2, and miR-328
SIRT1
(42)
(44)
(44)
(35)
(43)
(50)
(51)
Integrin signaling Osteosarcoma
Lung adenocarcinoma
Pancreas adenocarcinoma
Colon–rectum adenocarcinoma
Gastric carcinoma
JNK, p38 MAPK, GADD45α, ERK/JNK-ElK-1, CArG, Egr-1 AP-1/JunD, MMP-
1, iNOS, α-MSH β-catenin, c-kit, and MITF
EMT: MMP-1, PI-3K/Akt/NF-κB, E-cadherin, N-cadherin, vimentin, MMP-2 and 
MMP-9, phospho-Akt and phospho-NF-κB, TGF-β, α5β1 integrins, hyaluronic 
acid, Snail, E-cadherin, and N-cadherin
(52, 53)
(54)
(56)
(27)
(33)
(53)
(55)
(56)
Developmental signaling 
pathways
Colon–rectum carcinoma
Ovarian carcinoma
Gastric carcinoma
Cervix adenocarcinoma and squamous 
cell carcinoma
Thyroid carcinoma
Glioblastoma
Wnt: Wnt2; Notch: TTF1, TTF2, Pax8
Notch: Notch1, NIS, Notch1 activation-dependent p53
STAT3: Erk1/2(MAPK), pSTAT1
Hh: GL1, Ihh, Ptch and Smo, PKC α and δ
(57)
(58)
(59)
(16)
(53)
(60)
Signal transduction by the 
transforming growth factor
Melanoma
Pancreas adenocarcinoma
Colon–rectum carcinoma
TGF-β, TGF-β1/Smads (17)
(23)
(24)
Apoptotic pathways
Prostate carcinoma
Nasopharynx carcinoma
Fibrosarcoma
Liver carcinoma
Hepatoma
Human epidermoid carcinoma
Ovarian carcinoma
Colon–rectum carcinoma cells
Colon–rectum carcinoma (DOX)
Lung (+As2O3)
Non-melanoma skin cancer cell (+CIS)
Liver carcinoma
Bcl-2, Bcl-X(L), survivin, Bax, Bak, PUMA, Noxa, Bim, TRAIL-R1/DR4 and 
TRAIL-R2/DR5, cytochrome c, Smac/DIABLO, and AIF
CASP (3, 8, and 9), PARP-1, myeloid cell leukemia 1 phospho-ERK and 
phospho-p38 expression
Atg5, Atg7, Atg9, and Atg12 proteins
p53, pRb-E2F/DP, Fas, FasL
Fas, Fas ligand, extracellular-signal-regulated kinases (ERK) ½, and p38 
expression
Fas/APO-1
(27)
(29)
(30)
(31)
(38)
(43)
(61, 62)
(64)
(65)
(29)
(Continued)
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Target in carcinogenetic 
processes
Cancer cells Molecular pathways Reference
Inflammatory pathway Colon–rectum carcinoma COX-2, NF-κB, AP-1, IL-6, IL-8, TNF-α, ICAM-1, MCP-1, miRNAs, and PPAR (15, 66, 67)
(68)
(69)
Immune surveillance Splenocytes IFN-γ, CD206, CD204, IL-10, TGF-β, EGF, MMP-9, IL-6, and IL-12 (71)
Macrophages and tumor-associated 
macrophages (TAM)
Hormone signaling Breast carcinoma Tif2, ERα, p53, and MAPK (70, 73)
Multidrug resistance Colon–rectum carcinoma (+5-FLU) Desmosomes, gap- and tight junctions (claudin-2) and adhesion molecules 
(E-cadherin – EMT)
(23)
Non-small cell lung cancer cells (+5-FLU) CASP 3, MMP-9 (32)
Non-melanoma skin cancer cell (+CIS) NF-κB, cytochrome c, Bcl-2 and Bax, Fas and FasL (38)
Lung adenocarcioma (+As2O3) Oxidative stress, cycle arrest at G1/S phase (43)
Colon carcinoma (+DOX) TOPO2 (64)
(38)
aIn italics are reported negative results (lack of anti-cancer activity on the selected target).
TABLe 2 | Continued
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prooxidant effects can have effect on carcinogenesis, despite the 
debate is still open regarding their relevance on chemopreven-
tion. The antioxidant properties are assumed to protect cells from 
oxidative damage; however, prooxidant activities are held likely 
to be responsible for their cytotoxic or proapoptotic effects. As 
chemopreventive agent, resveratrol chronic supplementation 
reduced DNA leukocytic damage, altering the prooxidant/anti-
oxidant balance, in a rat model of colon carcinogenesis induced 
by 1,2-dimethylhydrazine (22). The increase of antioxidant 
status occurred via both enzymatic mechanisms, involving 
superoxide dismutase (SOD), catalase (CAT), glutathione 
reductase, glutathione peroxidase, and glutathione S-transferase, 
as well as non-enzymatic mechanisms, associated with reduced 
glutathione, vitamin C, vitamin E, and β-carotene (22). A signifi-
cant decrease in lipid peroxidation markers (thiobarbituric acid 
reactive substances, diene conjugates, and lipid hydroperoxides) 
was also reported (22). Conversely, as chemotherapeutics, 
resveratrol, used in combination with As2O3 against lung 
adenocarcinoma cells, enhanced apoptosis-inducing oxidative 
stress (23). In agreement, the effect of the resveratrol derivative, 
3,3′,4,4′-tetrahydroxy-trans-stilbene, on viability, apoptosis, and 
proliferation of ovarian cancer cells included the influence on cell 
red–ox homeostasis (24). The antiapoptotic activity was associ-
ated with the cysteine-dependent aspartate specific proteases, 
namely, “caspases” (CASP) 3, 8, and 9, and p38 MAPK, which 
were stimulated more efficiently with the derivative than the par-
ent drug (24). This effect coincided with increased reactive oxygen 
species (ROS) generation, downregulated SOD and CAT activi-
ties, excessive accumulation of 8-hydroxy-2′-deoxyguanosine, 
and its insufficient repair due to decreased expression of DNA 
glycosylase I (24). Moreover, the effects of resveratrol and its 
three derivatives, i.e., 3,3′,4,4′-tetrahydroxy-trans-stilbene (M6), 
3,4,4′,5-tetrahydroxy-trans-stilbene (M8), and 3,3′,4,4′,5,5′-hex-
ahydroxy-trans-stilbene (M12), showed strong cytotoxicity 
against T cell leukemia Jurkat cells (25). The increased activity of 
CASP 3 and 9 was again observed, particularly in presence of M8 
and M12, short-living prooxidative metabolites; cell death was 
accompanied by the loss of mitochondrial potential, oxidative 
stress, decrease of glutathione levels as well as the loss of both 
mRNA expression and activity of manganese-dependent super-
oxide dismutase (MnSOD) (25).
The balance between antioxidant and prooxidant effects of 
resveratrol is still controversial, being dependent on the dosage 
in use for testing. Given the above reported results, two major and 
opposite functions of this phytochemical can be found: the first 
related to its chemoprevention activity associated with antioxi-
dant effect in order to reduce impairment of damage of essential 
biomacromolecules; the second related to its chemotherapeutic 
potential, associated with the induction of ROS generation in 
cancer cells, leading to their enhanced apoptosis.
Biological Outcomes of Growth Factor 
Signaling: Cell Proliferation and  
Genome instability
Cell proliferation is the combination of two distinct processes: 
(i) cell cycle, including cell division and genome segregation 
(mitosis) and (ii) cell growth, under the influence of many growth 
factors. The four phases composing the mammalian cell cycle, 
i.e., S (DNA synthesis) and M (mitosis) separated by gap phases, 
G1 and G2, are mainly regulated by cyclin-dependent kinases 
(CDKs), and E3 ubiquitin ligases, which mediate targeted protein 
degradation. Several phytochemicals inhibit cancer cell prolifera-
tion by modulating the genes accounted to control several aspects 
of cell cycle, including the activity cyclins and CDKs. Cell cycle 
arrest is an irreversible process, which, ultimately, can result in 
the apoptotic cell death.
Resveratrol inhibited oral squamous cell carcinoma cell lines 
by inducing apoptosis and cell cycle arrest at G2/M transition, 
in a concentration- and time-dependent manner, enhancing the 
expression of cyclin A2 and cyclin B1 (26). Similar findings were 
reported for the resveratrol analog (E)-4-(3,5-dimethoxystyryl)
phenyl acetate (Cmpd1), highly active against glioblastoma, one 
of the most malignant form of adult brain tumor with a very poor 
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prognosis: Cmpd1 reduced glioblastoma cell colony formation, 
arresting cell cycle at G2/M phase transition and suppressing 
cyclin D1 and cyclin B1 expression (27).
Inducing the arrest at G1-phase, resveratrol resulted in a 
time- and dose-dependent inhibition A431 human epidermoid 
carcinoma cell growth, particularly by modulating the CDK 
inhibitor-cyclin-CDK machinery (28). Resveratrol treatment 
caused induction p21Cip1 (or p21Waf1), a CDK inhibitor 1 also called 
CDK-interacting protein 1, decreasing the protein expressions of 
cyclin D1, cyclin D2 and cyclin E as well as of CDK2, CDK4, and 
CDK6, which were also reduced in their activity (28). Analogous 
cycle arrest at G1-phase was also reported for liver carcinoma (29) 
and hepatoma (30) cell lines. To further support the findings on 
A431 cell line, Ahmad et al. also demonstrated the effect of res-
veratrol on retinoblastoma protein (pRb) and the E2F families of 
transcription factors, which are essential proteins for G1/S phase 
transition, mediating apoptotic cell death (31). Similar results 
were, then, reported for non-melanoma skin cancer cells by Cosco 
and colleagues (32). Authors provided evidence of the pRb-E2F/
DP pathway as important contributor of resveratrol-mediated 
cell cycle arrest and apoptosis; indeed, resveratrol produced a 
dose- and time-dependent decrease in the hyperphosphorylated 
pRb with a relative increase in hypophosphorylated pRb, com-
promising the availability of free E2F and downregulating protein 
expression of five E2F (1–5) (31). The E2F factors drive cell to 
apoptosis, binding to DNA as homodimers or heterodimers in 
association with dimerization partner (DP) 1 and 2 (31).
The cell cycle arrest at S-phase and further apoptosis was 
observed after resveratrol treatment in anaplastic thyroid carci-
noma cells, an extremely aggressive and undifferentiated tumor, 
for which conventional treatments are usually not effective (33). 
Resveratrol metabolites, i.e., resveratrol 3-O-d-glucuronide 
and resveratrol 4′-O-d-glucuronide (but not resveratrol 3-O-d-
sulfate), showed similar effects in colon cancer cells, with G1/S 
phase arrest mediated by A3 adenosine receptors and cyclin D1 
depletion (34).
The effects of resveratrol on cell cycle arrest and cell prolifera-
tion appeared to be also modulated by its specific targeting toward 
long non-coding RNAs (lncRNAs), which are transcripts longer 
than 200 nucleotides, currently considered the new avenue for 
chemoprevention. Changes in the expression of lncRNAs were 
reported in several forms of cancer and proposed as molecular 
target for phytochemicals. At microarray analysis, resveratrol 
downregulated the tumor-related lncRNA, called AK001796, in 
lung cancer cell line (35).
In summary, resveratrol has the function of reducing cell 
growth and inhibiting cell proliferation directly acting on cell 
cycle, growth factors, CDKs, and transcription factors. All 
together, these effects lead to the resveratrol-enhanced chemo-
prevention, by modulating genes involved in cancer cell initiation 
and proliferation as well as promoting cancer cell apoptosis.
Beyond cell growth, a further biological outcome of growth 
factor signaling is the genomic instability, major driving force for 
carcinogenesis since able to increase the tendency to accumulate 
genetic alterations, during the life cycle of cells. During cell divi-
sion, genomic instability is usually minimized via high-fidelity 
DNA replication in S-phase, correct chromosome segregation in 
mitosis, and error repair of sporadic DNA damage. A well-docu-
mented anticancer mechanism of resveratrol works on blocking 
topoisomerase (TOPO) activity, a family of enzymes that regulate 
the over-winding or under-winding of DNA. Resveratrol, above 
all, interferes with TOPO II-α (TOPO2), involved in the resolu-
tion of super-coiled DNA and chromosome segregation during 
mitosis and over-expressed in cancer cells. Resveratrol, indeed, 
induced a delay in S-phase progression with the concomitant 
phosphorylation of the histone H2AX (H2A histone family, 
member X), which, in turn, inhibits TOPO2 (36, 37). Phase II 
metabolites of resveratrol displayed the same effects (38). Rusin 
and co-workers also demonstrated as resveratrol was associated 
with highly instable telomeres, phosphorylating the histone 
H2AX at serine 139 and p53 at serines 15 and 37, and activating 
DNA signaling (39), signs of senescence, including the impaired 
expressions of “BReast and ovarian CAncer growth-suppressor 
protein” (BRCA)-1, cyclin B1, pRb, and p21, were detectable, too 
(39). Nonetheless, resveratrol was associated with the prolonga-
tion of the TOPO–DNA complex, as reported for gliobastoma 
cells (40) and for breast and colon cancer cells, where the com-
pound also correlated to lower nuclear levels of human telomerase 
reverse transcriptase (hTERT) (41). All together, these findings let 
resveratrol acquiring the role of “topoisomerase poison,” although 
data on osteosarcoma and lung cancers are still debated (39).
To date, resulting data support the role of resveratrol as 
chemotherapeutic agent, able to induce cell death specifically 
acting on TOPO2.
Cytoplasmic Tyrosine Kinase Signaling
Cytokine Signaling
Several types of cancer are to some extent promoted by a certain 
degree of systemic, low-grade chronic inflammation, character-
ized by elevated circulating inflammatory biomarkers, such 
as cytokines (e.g., interleukin (IL)-8, IL-6, IL-1, and IL-12), 
prostaglandin E2 (PGE2), tumor necrosis factor α (TNF-α), and 
interferon (INF).
Resveratrol mainly acts on TNF-α expression and related 
signaling pathways. Noteworthy, considering human embryonic 
kidney cell line, resveratrol suppressed TNF-α-induced signaling 
in dose-dependent manner, both via nuclear factor kappa-B (NF-
κB) activation and via transcriptional activity of p65, but without 
affecting the expression of the former or blocking the nuclear 
translocation of the latter (42). Resveratrol inhibited DNA-
binding activity of NF-κB and IKKα degradation and blocked the 
ubiquitination of NF-κB essential modifier (NEMO), a subunit 
of the IκB kinase complex that activates NF-κB, but inhibits 
NF-κB kinase subunit gamma (IKK-γ) (42). In colon carcinoma 
cancer (CRC) cells, the downregulation of NF-κB activation and 
its translocation to the nucleus, as well as the downregulation of 
gene end products regulated by NF-κB, i.e., matrix metallopro-
teinase (MMP)-9 and CASP 3, were both mediated through the 
inhibition of NF-κB inhibitor α (IκBα) kinase (43).
A further involvement of the TNF-α signaling in the  anticancer 
effect of resveratrol is associated with the radio- and chemoin-
ducible cancer gene therapy vector “Ad.Egr-TNF,” a replication-
deficient adenovirus expressing human TNF-α under control of 
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the early growth response (Egr)-1 promoter (44). In rat tumor 
xenograft models, resveratrol induced the Egr-1 expression 
from its chromosomal locus [Egr-1 promoter CC(A +  T) rich 
GG sequences], showing anticancer response with the increase 
of TNF-α (44). Interestingly, the inhibition of the nicotinamide 
adenine dinucleotide-dependent protein deacetylase, called 
sirtuin (SIRT)-1, a reported target of resveratrol, appeared to 
not abrogate the induction of Egr-1 expression, thus excluding a 
SIRT-mediated mechanism of action, in this case (44).
However, data support as SIRT1 decreases apoptosis through 
deacetylation of p53; resveratrol is known as an activator of SIRT1 
(45) as well as of the gene expression levels of SIRT1, SIRT3, and 
SIRT4 as reported in the liver of wild-type zebrafish (46). Authors 
also documented resveratrol activity on peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1α), which is 
a transcriptional coactivator that regulates the genes involved in 
energy metabolism, and nicotinamide phosphoribosyltransferase 
(NAMPT), an enzyme which contributes to the biosynthesis of 
nicotinamide adenine dinucleotide, promoting vascular smooth 
muscle cell maturation, inhibiting neutrophil apoptosis, and 
activating insulin receptor (46). SIRT/NAMPT interacts with 
the acetylation of p53: using the 293T cell line (HEK293 cells 
transformed with large T antigen), the apoptosis induced by 
an inhibitor of NAMPT pathway was associated with increased 
acetylation of p53 at Lys382, which is required for the func-
tional activity of p53 (47). Resveratrol, as SIRT1 activator, also 
ameliorated cisplatin-induced acetylation of p53, apoptosis, and 
cytotoxicity in mouse proximal tubular cells cells: SIRT1 activa-
tion by resveratrol decreased cisplatin-induced apoptosis while 
improving the glomerular filtration rate and resveratrol also 
remarkably blocked cisplatin-induced decrease of Bcl-xL (45). 
Taken together, findings suggest that the modulation of p53 by 
SIRT1 could be a possible target to attenuate cisplatin-induced 
kidney injury. Similarly, resveratrol alleviated doxorubicin 
(DOX)-induced myotoxicity (48) and cardiotoxicity (49) via 
SIRT1-dependent mechanisms.
The regulatory activity of resveratrol on sirtuins is also rel-
evant in terms of antiageing effects. By regulating these histone 
deacetylase, resveratrol mimics caloric restriction, thus prolong-
ing lifespan.
Integrin Signaling
Integrins are transmembrane proteins that facilitate the interac-
tion of cells with the extracellular environment, strongly impli-
cated in cancer progression. Transcriptional factors are the main 
elements influenced by integrins, although, in the last decades, 
a further integrin mediated process acquired more and more 
importance: the epithelial–mesenchymal transition (EMT), key 
player for tumor invasion and metastasis.
Considering the effect of resveratrol on transcriptional 
factors, besides the above described NF-κB (see Cytokine 
Signaling), resveratrol also inhibits several further transcrip-
tional factors, including activator protein (AP)-1, AP-2, and 
CREB, which act, independently or in coordination, to control 
genes involved in regulating urinary plasminogen activator 
(u-PA) and several MMPs (35). When tested on osteosarcoma 
cells, resveratrol reduced their in vitro migration and invasion 
through transcriptional and epigenetic regulation of MMP-2; 
this finding was corroborated by in  vivo experiments, which 
observed a decreased incidence of lung metastasis (35). From 
the molecular point of view, MMP-2 activity reduction was 
controlled via inhibition of CREB–DNA-binding activity and 
upregulation of miR-328, involving c-Jun N-terminal kinases 
(JNK) and p38 MAPK signaling pathways, respectively (35). 
Considering cancer suicide gene therapy for the treatment 
of lung adenocarcinoma, preclinical data support the use of 
resveratrol-responsive CArG domain elements [CC(A/T)6GG] 
from the Egr-1 promoter, in order to promote apoptosis and 
reduce the risk of metastasis (50). In lung adenocarcinoma cells, 
when combined with resveratrol, both synthetic and natural 
Egr-1 promoters induced the expression of the exogenous (but 
not the endogenous) nuclear protein called “growth arrest and 
DNA damage” (GADD)-45α, particularly responsive to genomic 
instability finally promoting apoptosis via ERK/JNK-ElK-1 
pathway (50). Resveratrol-induced reduction of cell invasion 
was also observed and associated with a decreased expression 
of AP-1/JunD, MMP-1, B-cell lymphoma (Bcl)-2, inducible 
NOS (iNOS), and those molecules related to alpha-melanocyte-
stimulation hormone (α-MSH) signaling, e.g., β-catenin, c-kit, 
and microphthalmia transcription factor (MITF) (51).
Currently, the overwhelming activity of resveratrol on 
integrin signaling has been associated with the arrest of EMT, 
opening innovative ways to treat highly metastatic and life-
threatening tumors, such as the pancreatic adenocarcinoma. 
Resveratrol inhibited, in a dose-dependent manner, EMT 
of pancreatic cancer cells, by suppressing both the PI3K/
AKT/NF-κB pathway and the EMT-related gene expression 
(E-cadherin, N-cadherin, vimentin, MMP-2, and MMP-
9), pivotal for cancer cell motility and metastasis (52, 53). 
Consistently, resveratrol reduced the levels of phospho-AKT 
and phospho-NF-κB in pancreatic cancer cells, and counter-
acted the alterations of cell morphology, typical of EMT and 
cell invasion, induced by the transforming growth factor-β 
(TGF-β) (53). Along the same direction, resveratrol decreased 
the levels of cell adhesion proteins and EMT mediators: α5β1 
integrins and hyaluronic acid were repressed in ovarian cancer 
cell lines (54); N- and E-cadherins and the protein able to pro-
mote their suppression, i.e., Snail family Zinc finger 1 (SNAI1, 
also called Snail), were decreased in gastric (55) and CRC 
cells (56). Resveratrol, moreover, potentiated the antitumor 
effects of 5-fluoruracyl (5-FLU) on CRC cells enhancing their 
chemosensitization and attenuating the drug resistance: the 
mechanism involved the suppression of EMT phenotype, with 
the upregulation of intercellular junctions and E-cadherin, and 
the downregulation of NF-κB and vimentin (43).
Developmental Signaling Pathways
Multiple cellular developmental signaling pathways have been 
involved in the processes of cancer cell invasion, metastasis, and 
tumor relapse. Wingless integration (Wnt), Notch, Hedgehog 
(Hh), and signal transducer and activator of transcription 
(STAT3) are crucially implicated in the embryonic development, 
in the biology of cancer stem cells (CSCs) and in the acquisition 
of EMT. Resveratrol, in particular, has been reported to act mostly 
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on STAT3 (57) and Notch signaling (33). Zhong et al. reported 
that resveratrol reduced gene activation and protein expression of 
STAT3, Notch, and Wnt signaling in ovarian cancers, enhancing 
G1 phase accumulation and increasing apoptosis (53). Again, in 
cervical adenocarcinoma and squamous cell carcinoma cell line, 
resveratrol inhibited cell growth by promoting apoptosis via sup-
pression of STAT3, Notch1, and Wnt2 signaling pathways (58). 
Considering human biopsies of cervical cancer, the immunohis-
tochemical staining on tissue microarrays revealed significantly 
higher frequencies of Notch1, Notch2, Hes1, Wnt2, Wnt5a, 
p-STAT3, and β-catenin nuclear translocation than in healthy 
controls (58). On the other hand, the protein inhibitor of activated 
STAT3 (PIAS3), which is an E3 small ubiquitin-related modifier 
(SUMO)-protein ligase, was remarkably low in tumor specimens 
(58). In agreement with these findings, resveratrol suppressed 
the Wnt signaling in both normal and tumor colon mucosa in 
a phase I pilot trial on eight colon cancer patients (57) and also 
inhibited the Notch1 pathway in anaplastic thyroid carcinoma cell 
line, following a dose-dependent manner (33). In the latter case, 
resveratrol upregulated the expression of thyroid-specific genes, 
including thyroid transcription factor (TTF)-1 and TTF-2, paired 
box (Pax)-8, and sodium iodide symporter, inducing functional 
Notch1 protein expression and activation of transcriptional fac-
tors related to this pathway (33). Similarly, resveratrol promoted 
the apoptosis in glioblastoma cells via the wild-type p53 restora-
tion, dependent from the Notch1 signaling (59).
The resveratrol analog Cmpd1 further support the role of 
STAT3 in anticancer molecular mechanism of this phytochemical: 
glioblastoma cells, in particular, harbor aberrantly active STAT3 
and the treatment with Cmpd1 suppressed the STAT3 tyrosine705 
phosphorylation in a dose-dependent manner, concomitantly 
with the induction of the STAT3 pserine727 and Erk1/2 (27). 
Cmpd1 also blocked EGF-stimulated pSTAT1 induction (27).
Besides STAT3, Notch, and Wnt, the Hedgehog (Hh) signaling 
pathway plays a pivotal role in carcinogenesis and, specifically, 
in EMT promotion, representing an important target for res-
veratrol. In gastric cancer, resveratrol reduced the expressions 
of glioblastoma (GL)-1, a protein originally isolated in human 
glioblastoma and key effectors of the Hh pathway during embryo 
development and upregulated in many tumors (55). Decreasing 
the levels of crucial integrins for EMT, such as Snail, E-cadherin, 
and N-cadherin, resveratrol suppressed the cell viability and inva-
sion similarly to what occurred in presence of cyclopamine (55). 
The phytochemical also reduced mRNA and protein levels of the 
following Hh signals: the Indian hedgehog homolog (Ihh) and 
the surface transmembrane protein, called Patched (Ptch), which 
prevents the high expression of the seven membrane spanning 
receptor, namely, smoothened (SMO) (56). Resveratrol, finally, 
regulated the expression of protein kinase C (PKC) α and δ, in 
a time- and dose-dependent manner, similarly to 5-FLU used as 
positive control (56).
Signal Transduction by the Transforming Growth 
Factor-β Super-Family
TGF-β super-family has been widely implicated in various cel-
lular processes, including cell proliferation and differentiation, 
immune modulation, and extracellular matrix remodeling. 
TGF-β exhibits antiproliferative functions by activating signaling 
pathways that mediates cell cycle arrest and induction of apopto-
sis. It also exerts effects through heteromeric receptor complexes 
consisting of type I and type II serine/threonine kinase receptors. 
The signaling pathway is initiated by the ligand binding to the 
TGF-β RII cell surface receptor, which, in turn, recruits the TGF-
β RI kinase. The latter phosphorylates the receptor-regulated son 
of mothers against decapentaplegic (R-SMAD) proteins, namely, 
Smad2 and Smad3. Activated R-Smads form a complex with the 
common-mediator Smad (Co-Smad), called Smad4, which then 
moves directly to the nucleus. The complex can either act as a 
co-activator or DNA-binding transcription factor, participating 
in the regulation of several target gene expression (e.g., p15, p21, 
and c-myc). TGF-β is further controlled by a third class of Smads, 
the inhibitory Smads (i-Smads), named Smad6 and Smad7 pro-
teins, which block the activation of R-SMADs and Co-SMADs. 
TGF-β signaling, at later stages, can induce EMT.
Resveratrol, particularly, reduced the alterations of cell mor-
phology induced by TGF-β, typical of EMT and cell invasivity, 
via AKT and NF-κB (53). Similar findings were reported for CRC 
in vitro and in vivo: the expression of E-cadherin, via transcrip-
tion factors Snail, was increased, while vimentin expression and 
the activation of the TGF-β1/Smads signaling pathway were 
reduced (60).
Apoptotic Pathways
Programed cell death, or apoptosis, is a highly conserved 
physiological cell suicide response, crucial for mammalian 
tissue homeostasis. Cell apoptosis is triggered in response to 
endogenous stimuli (e.g., growth factor deprivation) or exog-
enous stimuli (e.g., irradiation or genotoxic chemotherapeutic 
drugs). Mammalian apoptotic pathways are greatly controlled 
by a plethora of molecular mechanisms, which involve both 
antiapoptotic proteins, such as Bcl-2, and proapoptotic proteins, 
such as CASPs and FAS ligand (FAS-L). Over-expression of Bcl-2 
family proteins inhibits the release of cytochrome c from the 
mitochondrial intermembrane space into the cytosol, which is a 
decisive event triggering apoptosis. CASPs possess a wide range 
of expression patterns throughout mammalian tissues and are 
usually organized into a cascade of proteins: some CASPs are 
“initiators” (CASP-8, 9, and 10) and sequentially process and 
activate other CASPs, called “executioners” (CASP-3, 6, and 7). 
The FAS receptor (FasR) is a surface death receptor able to bind 
its specific ligand to lead cell toward apoptosis: it is also known as 
apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 
(CD95), or TNF-receptor super-family member 6 (TNF-R-SF6). 
After binding, the death domain (DD) aggregation produces the 
receptor complex internalization via endosomes; this allows the 
adaptor molecule to bind the DD of Fas through its own DD, 
resulting in the formation of Fas-associated protein with death 
domain (FADD). FADD also contains death effectors domain, 
which facilitates binding to CASP-8.
As demonstrated on prostate cancer cells, the molecular 
mechanisms of resveratrol exploit the interactive effects with 
TNF-related apoptosis-inducing ligand (TRAIL), a protein that 
works as a ligand and induces the process of programed cell death. 
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Prostate cancer androgen-dependent LNCaP cells, in particular, 
are resistant to TRAIL, and the downregulation of PI3K/AKT 
pathway by resveratrol can sensitize cells toward TRAIL-mediated 
apoptosis. Treatment of LNCaP cells with resveratrol resulted in 
generation of ROS; translocation to mitochondria of both Bcl-
2-like protein 4, also called Bcl-2-associated X protein (Bax), 
and p53 tumor suppressor protein, with the subsequent drop 
in mitochondrial membrane potential. Released mitochondrial 
proapoptotic proteins include, among the oth ers, cytochrome c 
CASP-3 and CASP-9, apoptosis-inducing factor (AIF), second 
mitochondria-derived activator of caspase/direct inhibitor of 
apoptosis-binding protein with low pI (Smac/DIABLO) and 
protein high temperature requirement serine protease A2 
(HtrA2), also known as Omi (61, 62). Smac was, in particular, 
investigated and authors found that Smac small interference 
RNA (siRNA) inhibited resveratrol-induced apoptosis, whereas 
Smac N7 peptide induced apoptosis, enhancing the effective-
ness of resveratrol (61, 62). In the same work, resveratrol also 
augmented the expression of further proapoptotic proteins, i.e., 
Bax, Bcl-2 -antagonist/killer-1 (Bak), p53 upregulated modula-
tor of apoptosis (PUMA), the Bcl-2 Homolog (BH)3-containing 
proteins (called Noxa and Bim), TRAIL death receptors  –  R1/
DR4 and R2/DR5 (61, 62). Conversely, resveratrol downregulated 
the expression of antiapoptotic proteins, including Bcl-2, Bcl-XL, 
survivin, and XIAP (61, 62) Resveratrol had no effect, instead, 
on normal human prostate epithelial cells and also the ability of 
the phytochemical to sensitize TRAIL-resistant LNCaP cells was 
inhibited by the presence of dominant negative FADD, CASP-8 
siRNA, or N-acetylcysteine (61, 62). Similar anticancer effects of 
resveratrol was observed on fibrosarcoma cells, where the expres-
sion of apoptosis-associated genes resulted altered in microarray 
analyses (63), as well as on nasopharyngeal cancer cells and 
non-small cell lung cancer cells, where resveratrol inhibited cell 
viability and promoted apoptosis by activating citocrome c (64), 
CASP-3 and altering the Bax/Bcl-2 apoptotic signaling (65).
Again, the resveratrol derivative, 3,3′,4,4′-tetrahydroxy-trans-
stilbene, and the analog cmpd1 stimulated CASP activity (3, 8, and 
9) in ovarian cancer cells (24), glioblastoma cells (27) and ovarian 
cells (17); in the latter two cases, resveratrol also induced cleav-
age of poly(ADP ribose) (PARP-1) (17) and suppressed survivin, 
myeloid cell leukemia 1, B-cell lymphoma-extra-large (Bcl-xL) 
(27). In Huh-7 cells, a human hepatoma cell line system infected 
by hepatitis C virus, resveratrol promoted the expression of proa-
poptotic proteins, which was associated with the mitochondrial 
membrane depolarization and the increase in CASP activity (30). 
However, the phytochemical had no effect on death receptor Fas, 
FasL, ERK ½, and p38 expression, while downregulated phospho-
ERK and phospho-p38 expression (30), triggering autophagic cell 
death through increased expression of autophagy-related genes 
(Atg)-5, Atg7, Atg9, and Atg12 (30). Consistently, the antipro-
liferative activity of resveratrol was reported also in two human 
liver cancer cell lines, Hep p53-positive G2 and p53-negative Hep 
3B. Resveratrol inhibited cell growth in p53-positive Hep G2 cells 
only, as a result of apoptotic cell death via p53-dependent path-
ways (29). These cells, arrested at G1 phase, showed the increase 
of p21 and Bax expression, but not of Fas/APO-1 apoptotic sign-
aling pathway (29). Conversely, when tested in combination with 
As2O3, resveratrol synergistically increased not only the release 
of cytochrome c, but also the expressions Fas and FasL, and the 
apoptotic pathways mediated by oxidative stress (23).
In addition to p53 pathway, resveratrol contributed to trigger 
apoptosis via pRb-E2F/DP, as demonstrated in A431 human 
epidermoid carcinoma cells (31).
These findings identify resveratrol as a powerful proapop-
totic agent, which is able to trigger different pathways leading 
to both mitochondrial and non-mitochondrial programed cell 
death, in a number of cancer cells. Noteworthy, the stilbene can 
sensitize resistant cancer cells without significantly affecting 
normal (non-cancer) cells.
inflammatory Pathway
Inflammation is a critical component of tumor progression with a 
key role within the tumor microenvironment. Signaling molecules 
of the innate immune system are, indeed, involved in cancer inva-
sion, migration, and metastasis, such as selectins, chemokines, 
and their receptors. These observations could be used for new 
inflammatory therapeutic approaches against cancer develop-
ment that could involve inflammatory agents, from non-steroidal 
inflammatory drugs (NSAIDs), selective cyclooxygenase-2 
(COX-2) inhibitors to natural products, mainly phytochemicals.
Resveratrol is a promising molecule able to target multiple 
inflammatory, cancer-related sites, simultaneously, i.e., mac-
rophage migration inhibitory factor, COX-2, NF-κB, and AP-1 
(15, 66, 67). In particular, this compound is a strong COX sup-
pressor, and an activator of peroxisome proliferator-activated 
receptor (PPAR) (68). Recent evidence supports the role of 
microRNAs (miRNAs) in the beneficial effects of resveratrol, with 
emphasis on its inflammatory effects: it decreased the secretion 
of pro-inflammatory cytokines (e.g., IL-6, IL-8, and TNF-α), the 
expression of adhesion proteins, such as intercellular adhesion 
molecule (ICAM)-1, and of leukocyte chemoattractants, includ-
ing monocyte chemoattractant protein (MCP)-1, and it increased 
the production of inflammatory cytokines (67). Although 
without a clear mechanistic link, resveratrol activity appeared to 
be partially dependent from an impaired expression of certain 
miRNAs associated with inflammatory and tumor suppression 
effects (miR-663), proinflammatory effects (miR-155), or onco-
genicity (miR-21).
To date, however, evidence is particularly sound in sustain-
ing the anti-inflammatory activity of resveratrol, over the others 
natural molecules, to counteract the proliferation of CRC (69) 
and MCF-7 breast cancer cell line, via p53-COX-2 pathway (70).
Inflammation milieu is pivotal in cancer development, par-
ticularly in chronic inflammatory conditions. Resveratrol anti-
inflammatory activity is well-documented in a number of cancer 
cells and it is based on different mechanisms, thus contributing 
to explain the plethora of anticancer pathways synergistically 
regulated by this polyphenol.
immune Surveillance
In the last decades, several molecular mechanisms related to 
the immune activation have been demonstrated to protect 
against the onset of tumor cells, supporting the immunotherapy 
against cancer. The dysfunction of the host’s immune system, 
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conversely, is associated with the suppression of tumor immu-
nosurveillance and, in particular, T cell anergy, the presence of 
regulatory T cells and systemic defects of dendritic cells have been 
reported to be the main responsible factors of immune evasion. 
Immunosurveillance suppression involves resistance to apopto-
sis, secretion of immunosuppressive cytokines, reduced expres-
sion of major histocompatibility complex class I antigens and 
immunomodulatory molecules. Both host- and tumor-related 
mechanisms can lead to a progressive failure of the tumor-specific 
immune response, limiting the success of cancer immunotherapy.
Macrophages, particularly, inhibited or promoted the 
growth and spread of cancer, depending on their activation 
state. Treatment with the synthetic resveratrol analog HS-1793 
significantly increased IFN-γ secreting cells in splenocytes, and 
also decreased CD206+ macrophage infiltration, compared to 
CD68+ cells, in those tumor sites with a higher expression of 
IFN-γ (71). The local increase of IFN-γ modulated the status 
of tumor-associated macrophages (TAM) associated with the 
cancer microenvironment: human monocytic cell line THP-1 
cells, stimulated with phorbol-12-myristate-13-acetate, differen-
tiated to macrophages with M2-like phenotypes, which display 
TAM-like properties (71). The latter include high level of CD206, 
CD204, IL-10, TGF-β, EGF, MMP-9 and low levels of IL-6 and 
IL-12, able to promote tumor cell invasion (71). Upon IFN-γ 
exposure, THP-1-derived TAM changed their phenotypes to 
M-1-like morphology and intracellular granular pattern, showing 
increased levels of pro-inflammatory and immunostimulatory 
cytokines, and a reduction in immunosuppressive and tumor 
progressive mediators (71).
Evidence on the effects of resveratrol on cancer immunesur-
veillance is still scanty, and more mechanistic data are needed 
with non-synthetic resveratrol derivatives.
Hormone Signaling
The estrogenic activity has been recently reported for resveratrol 
and for its blood-circulating metabolites, applying a yeast two-
hybrid detection system, which relies on the interaction between 
the ligand-binding domain of the human estrogen receptors (ERs) 
α and β and the human co-activator transcriptional intermediary 
factor (Tif)-2 (72). Only the metabolite resveratrol-3-O-sulfate 
displayed strong, estrogenic activity via ERα-preferential antago-
nistic pathway, as confirmed in a human breast adenocarcinoma 
cell line (72). Consistently, the presence of 17-beta-estradiol 
further enhanced MAPK activation induced by resveratrol, but 
blocked the resveratrol-enhanced apoptosis, via inhibiting the 
p53-directed transcriptional activity, the p53 phosphorylation at 
serines 15, 20, and 392, and the p53 acetylation, in a concentra-
tion- and time-dependent manner (73). All these effects were 
arrested by the inhibitor of the nuclear ERα (73).
Beyond estrogenic activity, the androgenic effect of resveratrol 
represents an important step toward novel anticancer strategies. 
Dihydrotestosterone (DHT) can promote breast cancer growth 
via several mechanisms and, in addition to binding to ERα, the 
DHT binds its specific membrane receptor on integrin αvβ3. 
Interestingly, resveratrol can bind the plasma membrane integrin 
αvβ3, too, but it induces p53-dependent apoptosis. Therefore, 
resveratrol and DHT are both transducer, following the pathway 
of activated MAPK ERK1/2, but DHT enhances cell proliferation 
in cancer cells, while resveratrol promotes apoptosis (70). The 
mechanism of such diametrically opposed effect is dependent by 
two distinct types of ERK1/2 activation, each one associated with 
specific serine phosphorylation and acetylation of p53, mediated 
by separate surface receptor sites (70). In MCF-7 breast cancer, 
as a result, DHT inhibited several resveratrol-stimulated effects: 
(i) phosphorylation of Ser-15 of p53, (ii) COX-2/p53-dependent 
gene expression and nuclear complex of p53–COX-2 formation, 
essential for p53-dependent apoptosis, and (iii) p53-directed 
transcriptional activity (70).
In terms of chemoprevention, however, recent clinical findings 
do not support the use of resveratrol in the treatment of benign 
prostate hyperplasia (74). In a randomized placebo controlled 
clinical trial, two doses of resveratrol (150 or 1,000 mg, daily), 
administered for 4 months to 66 middle-aged men suffering from 
the metabolic syndrome, had no effects on prostate size and levels 
of prostate-specific antigen (PSA), testosterone, free testosterone 
and DHT (74). The highest dose of resveratrol, eventually, lowered 
the serum level of androstenedione, dehydroepiandrosterone 
(DHEA), and, mainly, dehydroepiandrosterone sulfate (DHEAS) 
(74), without a clear clinical significance.
Therefore, as reported above, resveratrol can target hormone 
signaling due to its anti-estrogenic activity relevant in hormone-
dependent cancers. However, the effects of this phytoestrogen on 
the androgen pathway should be further ascertained.
Multidrug Resistance
Cancer cells contain multiple aberrant signaling pathways that 
lead to drug resistance and therapy failure in many patients; thus, 
the multidrug therapy can possess higher efficacy against cancer 
cells than traditional therapies, by acting on diverse mechanisms 
simultaneously. As an example, the activated STAT3 signaling, 
above described as critical molecular target of resveratrol, appears 
a promising candidate in the management of resistant ovarian 
cancers (53). Considering gene therapy, the control of trans-
genic expression, via resveratrol activation, of Egr-1 promoter 
may sensitize cancer cells, extending the use of Ad.Egr-TNF to 
patients intolerant of radiation or chemotherapy, offering a novel 
tool for development of inducible gene treatments (44). Since 
these approaches are still seminal, resveratrol has been mostly 
investigated as adjuvant agent to be used in combination with 
classical chemotherapeutics, in the perspective of avoiding or 
reducing the risk of MDR.
Currently, resveratrol has been proposed as useful for antican-
cer therapy in combination with cisplatin (CIS) (64) and 5-FLU 
(32, 43), but not with DOX (38).
Resveratrol blocked the proliferation of both parental CRC 
cell lines (HCT116 and SW480) and their corresponding isogenic 
5-FLU-chemoresistant derived clones (HCT116R and SW480R), 
synergizing the inhibitory effects of 5-FLU against cell invasion 
(43). Interestingly, resveratrol induced a transition from 5-FLU-
induced formation of microvilli to a planar cell surface, con-
comitantly with the upregulation of desmosomes, gap- and tight 
junctions (claudin-2), and E-cadherin in both types of CRC cells 
(43). Along this direction, resveratrol- and 5-FLU were loaded 
together on ultra-deformable liposomes, in order to increase 
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their skin permeation: the perspective accounted the use of these 
agents to treat squamous cell carcinoma, actinic keratosis, Bowen’s 
disease, and keratoacanthoma (32). Strongly arresting cell pro-
liferation at G1/S phase, the multidrug liposomes improved the 
anticancer activity on human non-melanoma skin cancer cells as 
compared to both the free drug forms and the single entrapped 
agents (32). The ultra-deformable liposomes could accumulate in 
deeper skin layers and generate a skin depot of drugs, from which 
resveratrol and 5-FLU were slowly released (32).
The anticancer activity of CIS in combination with resveratrol 
has been tested in non-small cell lung cancer, in a dose- and time-
dependent manner (64). The increased apoptosis was associated 
with the depolarization of mitochondrial membrane potential, 
the release of cytochrome c from mitochondria to cytosol, and the 
abnormal expression of Bcl-2 and Bax proteins (64).
In combination with DOX, resveratrol displayed the interfer-
ence at the target enzymes, since both DOX and resveratrol act as 
TOPO inhibitors. In colon carcinoma cells, resveratrol, actually, 
counteracted DOX-induced formation of DNA-TOPO2 interme-
diates (38). At high concentrations (≥200 μM), resveratrol even 
diminished the intracellular concentrations of DOX, modulating 
its cytotoxic activity (38).
Resveratrol was added to arsenic trioxide (As2O3), a potent 
anticancer drug used for the treatment of acute promyelocytic 
leukemia and lung tumor, though largely compromised by MDR. 
In lung adenocarcinoma A549 cells, resveratrol potentiated the 
toxicity of As2O3, via apoptotic pathway (23). Resveratrol and 
As2O3 caused more genotoxicity and oxidative stress than the 
single agent, synergistically increasing the release of cytochrome 
c, the expressions of Fas and FasL, and apoptotic cell death via the 
induction of oxidative stress (23).
The chemosensitization of cancer cells to conventional 
chemotherapeutic agents represents an exciting field. In these 
terms, resveratrol represents a promising sensitizing agent in 
adjuvant therapy. Further studies should also ascertain its role in 
reverting radioresistance and in reducing the adverse effects of 
conventional therapies on non-target cells and tissues.
CONCLUSiON
Resveratrol appears a promising agent, relevant for both cancer 
chemoprevention and treatment. Several signaling pathways, 
involved in carcinogenesis and host defense response, are targets 
of its mechanism of action and mediate its pleiotropic anticancer 
activity. In the adjuvant therapy, in particular, resveratrol showed 
synergistic effects with 5-FLU and CIS chemotherapeutics, thus 
increasing cancer cell sensitization. The final perspectives are 
reducing adverse effects of conventional therapies to non-target 
cells and tissues, decreasing the risk of MDR and enhancing the 
global efficacy of treatments.
AUTHOR CONTRiBUTiONS
EV and MI conceived and designed the work, prepared the 
figures, and wrote the draft; AF and JS-R performed the data 
search and analysis, the figure and table preparation, and revised 
the draft.
ReFeReNCeS
1. Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from 
clinical studies. Avicenna J Phytomed (2015) 5:84–97. 
2. Rimando AM, Suh N. Biological/chemopreventive activity of stilbenes and 
their effect on colon cancer. Planta Med (2008) 74:1635–43. doi:10.105
5/s-0028-1088301 
3. Levi F, Pasche C, Lucchini F, Ghidoni R, Ferraroni M, La Vecchia C. 
Resveratrol and breast cancer risk. Eur J Cancer Prev (2005) 14:139–42. 
doi:10.1097/00008469-200504000-00009 
4. Bishayee A. Cancer prevention and treatment with resveratrol: from 
rodent studies to clinical trials. Cancer Prev Res (Phila) (2009) 2:409–18. 
doi:10.1158/1940-6207.CAPR-08-0160 
5. Varoni EM, Lodi G, Iriti M. Efficacy behind activity – phytotherapeutics are 
not different from pharmaceuticals. Pharm Biol (2015) 53:404–6. doi:10.310
9/13880209.2014.923000 
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
(2011) 144:646–74. doi:10.1016/j.cell.2011.02.013 
7. Lachenmeier DW, Godelmann R, Witt B, Riedel K, Rehm J. Can resveratrol in 
wine protect against the carcinogenicity of ethanol? A probabilistic  dose-response 
assessment. Int J Cancer (2014) 134:144–53. doi:10.1002/ijc.28336 
8. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol 
Nutr Food Res (2005) 49:472–81. doi:10.1002/mnfr.200500010 
9. Zunino SJ, Storms DH. Physiological levels of resveratrol metabolites are 
ineffective as anti-leukemia agents against Jurkat leukemia cells. Nutr Cancer 
(2015) 67:266–74. doi:10.1080/01635581.2015.989373 
10. Iriti I, Varoni E. Nutritional therapy: multitarget agents to prevent multifacto-
rial diseases. Oncodrugs (2013) 1:1e–2e. 
11. Iriti M, Varoni E. Biological and adjuvant therapies, new trends in oral cancer 
treatment. Oncodrugs (2014) 2:1e–2e. 
12. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cyto-
chrome P450 1A1 inhibitor. Biochem Biophys Res Commun (1999) 262:20–4. 
doi:10.1006/bbrc.1999.1152 
13. Diaz-Gerevini GT, Repossi G, Dain A, Tarres MC, Das UN, Eynard AR. 
Beneficial action of resveratrol: how and why? Nutrition (2016) 32:174–8. 
doi:10.1016/j.nut.2015.08.017 
14. Iriti M, Faoro F. Health-promoting effects of grape bioactive phytochemicals. 
In: Watson RR, editor. Complementary and Alternative Therapies and the Aging 
Population. London: Academic Press (2009). p. 445.
15. Britton RG, Kovoor C, Brown K. Direct molecular targets of resveratrol: 
identifying key interactions to unlock complex mechanisms. Ann N Y Acad 
Sci (2015) 1348:124–33. doi:10.1111/nyas.12796 
16. Kubota T, Uemura Y, Kobayashi M, Taguchi H. Combined effects of 
resveratrol and paclitaxel on lung cancer cells. Anticancer Res (2003) 23: 
4039–46. 
17. Hogg SJ, Chitcholtan K, Hassan W, Sykes PH, Garrill A. Resveratrol, 
 acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell 
aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstet 
Gynecol Int (2015) 2015:279591. doi:10.1155/2015/279591 
18. Strickland LR, Pal HC, Elmets CA, Afaq F. Targeting drivers of melanoma with 
synthetic small molecules and phytochemicals. Cancer Lett (2015) 359:20–35. 
doi:10.1016/j.canlet.2015.01.016 
19. Wong JC, Fiscus RR. Resveratrol at anti-angiogenesis/anticancer concentra-
tions suppresses protein kinase G signaling and decreases IAPs expression in 
HUVECs. Anticancer Res (2015) 35:273–81. 
20. Bommareddy A, Eggleston W, Prelewicz S, Antal A, Witczak Z, McCune DF, 
et al. Chemoprevention of prostate cancer by major dietary phytochemicals. 
Anticancer Res (2013) 33:4163–74. 
21. Bhattacharya S, Darjatmoko SR, Polans AS. Resveratrol modulates the malig-
nant properties of cutaneous melanoma through changes in the activation and 
14
Varoni et al. Anticancer Activity of Resveratrol
Frontiers in Nutrition | www.frontiersin.org April 2016 | Volume 3 | Article 8
attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma 
Res (2011) 21:180–7. doi:10.1097/CMR.0b013e3283456dfc 
22. Sengottuvelan M, Deeptha K, Nalini N. Resveratrol ameliorates DNA damage, 
prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat 
colon carcinogenesis. Chem Biol Interact (2009) 181:193–201. doi:10.1016/j.
cbi.2009.06.004 
23. Gu S, Chen C, Jiang X, Zhang Z. Resveratrol synergistically triggers apoptotic 
cell death with arsenic trioxide via oxidative stress in human lung adeno-
carcinoma A549 cells. Biol Trace Elem Res (2015) 163:112–23. doi:10.1007/
s12011-014-0186-2 
24. Mikuła-Pietrasik J, Sosińska P, Murias M, Wierzchowski M, Brewińska-
Olchowik M, Piwocka K, et  al. High potency of a novel resveratrol 
derivative, 3,3’,4,4’-Tetrahydroxy-trans-stilbene, against ovarian cancer 
is associated with an oxidative stress-mediated imbalance between DNA 
damage accumulation and repair. Oxid Med Cell Longev (2015) 2015:135691. 
doi:10.1155/2015/135691 
25. Kucinska M, Piotrowska H, Luczak MW, Mikula-Pietrasik J, Ksiazek K, 
Wozniak M, et  al. Effects of hydroxylated resveratrol analogs on oxidative 
stress and cancer cells death in human acute T cell leukemia cell line: prooxi-
dative potential of hydroxylated resveratrol analogs. Chem Biol Interact (2014) 
209:96–110. doi:10.1016/j.cbi.2013.12.009 
26. Yu X-D, Yang J-L, Zhang W-L, Liu D-X. Resveratrol inhibits oral squamous 
cell carcinoma through induction of apoptosis and G2/M phase cell cycle 
arrest. Tumour Biol (2015):1–7. doi:10.1007/s13277-015-3793-4 
27. Chelsky ZL, Yue P, Kondratyuk TP, Paladino D, Pezzuto JM, Cushman M, 
et al. Resveratrol analogue promotes ERKMAPK-dependent Stat3 serine and 
tyrosine phosphorylation alterations and antitumor effects in  vitro against 
human tumor cells. Mol Pharmacol (2015) 88:524–33. doi:10.1124/mol.115. 
099093 
28. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H. Resveratrol causes 
WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apop-
tosis in human epidermoid carcinoma A431 cells. Clin Cancer Res (2001) 
7:1466–73. 
29. Kuo P-L, Chiang L-C, Lin C-C. Resveratrol-induced apoptosis is mediated by 
p53-dependent pathway in Hep G2 cells. Life Sci (2002) 72:23–34. doi:10.1016/
S0024-3205(02)02177-X 
30. Liao P-C, Ng L-T, Lin L-T, Richardson CD, Wang G-H, Lin C-C. Resveratrol 
arrests cell cycle and induces apoptosis in human hepatocellular carcinoma 
Huh-7 cells. J Med Food (2010) 13:1415–23. doi:10.1089/jmf.2010.1126 
31. Adhami VM, Afaq F, Ahmad N. Involvement of the retinoblastoma (pRb)-
E2F/DP pathway during antiproliferative effects of resveratrol in human 
epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun (2001) 
288:579–85. doi:10.1006/bbrc.2001.5819 
32. Cosco D, Paolino D, Maiuolo J, Marzio LD, Carafa M, Ventura CA, 
et  al. Ultradeformable liposomes as multidrug carrier of resveratrol and 
 5-fluorouracil for their topical delivery. Int J Pharm (2015) 489:1–10. 
doi:10.1016/j.ijpharm.2015.04.056 
33. Yu X-M, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M, Chen 
H. Resveratrol induces differentiation markers expression in anaplastic 
thyroid carcinoma via activation of Notch1 signaling and suppresses cell 
growth. Mol Cancer Ther (2013) 12:1276–87. doi:10.1158/1535-7163.
MCT-12-0841 
34. Polycarpou E, Meira LB, Carrington S, Tyrrell E, Modjtahedi H, Carew MA. 
Resveratrol 3-O-D-glucuronide and resveratrol 4’-O-D-glucuronide inhibit 
colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin 
D1 depletion, and G1 cell cycle arrest. Mol Nutr Food Res (2013) 57:1708–17. 
doi:10.1002/mnfr.201200742 
35. Yang T, Wang L, Zhu M, Zhang L, Yan L. Properties and molecular mecha-
nisms of resveratrol: a review. Pharmazie (2015) 70:501–6. 
36. Basso E, Fiore M, Leone S, Degrassi F, Cozzi R. Effects of resveratrol on 
topoisomerase II-α activity: induction of micronuclei and inhibition of 
chromosome segregation in CHO-K1 cells. Mutagenesis (2013) 28:243–8. 
doi:10.1093/mutage/ges067 
37. Demoulin B, Hermant M, Castrogiovanni C, Staudt C, Dumont P. Resveratrol 
induces DNA damage in colon cancer cells by poisoning topoisomerase II and 
activates the ATM kinase to trigger p53-dependent apoptosis. Toxicol In Vitro 
(2015) 29:1156–65. doi:10.1016/j.tiv.2015.04.015 
38. Schroeter A, Groh IAM, Favero GD, Pignitter M, Schueller K, Somoza V, 
et al. Inhibition of topoisomerase II by phase II metabolites of resveratrol in 
human colon cancer cells. Mol Nutr Food Res (2015) 12:2448–59. doi:10.1002/
mnfr.201500352 
39. Rusin M, Zajkowicz A, Butkiewicz D. Resveratrol induces senescence-like 
growth inhibition of U-2 OS cells associated with the instability of telomeric 
DNA and upregulation of BRCA1. Mech Ageing Dev (2009) 130:528–37. 
doi:10.1016/j.mad.2009.06.005 
40. Leone S, Basso E, Polticelli F, Cozzi R. Resveratrol acts as a topoisomerase II 
poison in human glioma cells. Int J Cancer (2012) 131:E173–8. doi:10.1002/
ijc.27358 
41. Lanzilli G, Fuggetta MP, Tricarico M, Cottarelli A, Serafino A, Falchetti R, 
et al. Resveratrol down-regulates the growth and telomerase activity of breast 
cancer cells in vitro. Int J Oncol (2006) 28:641–8. 
42. Ren Z, Wang L, Cui J, Huoc Z, Xue J, Cui H, et al. Resveratrol inhibits NF-kB 
signaling through suppression of p65 and IkappaB kinase activities. Pharmazie 
(2013) 68:689–94. 
43. Buhrmann C, Shayan P, Kraehe P, Popper B, Goel A, Shakibaei M. Resveratrol 
induces chemosensitization to 5-fluorouracil through up-regulation of 
intercellular junctions, epithelial-to-mesenchymal transition and apoptosis 
in colorectal cancer. Biochem Pharmacol (2015) 98:51–68. doi:10.1016/j.
bcp.2015.08.105 
44. Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ, et al. 
Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. 
Cancer Gene Ther (2008) 15:133–9. doi:10.1038/sj.cgt.7701103 
45. Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, et  al. SIRT1 activation 
by resveratrol ameliorates cisplatin-induced renal injury through deacetyl-
ation of p53. Am J Physiol Renal Physiol (2011) 301:F427–35. doi:10.1152/
ajprenal.00258.2010 
46. Schirmer H, Pereira TCB, Rico EP, Rosemberg DB, Bonan CD, Bogo MR, 
et al. Modulatory effect of resveratrol on SIRT1, SIRT3, SIRT4, PGC1α and 
NAMPT gene expression profiles in wild-type adult zebrafish liver. Mol Biol 
Rep (2012) 39:3281–9. doi:10.1007/s11033-011-1096-4 
47. Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, Selvakumar D, 
et  al. Inhibition of NAMPT pathway by FK866 activates the function of 
p53 in HEK293T cells. Biochem Biophys Res Commun (2012) 424:371–7. 
doi:10.1016/j.bbrc.2012.06.075 
48. Sin TK, Tam BT, Yu AP, Yip SP, Yung BY, Chan LW, et al. Acute treatment of 
resveratrol alleviates doxorubicin-induced myotoxicity in aged skeletal muscle 
through SIRT1-dependent mechanisms. J Gerontol A Biol Sci Med Sci (2015). 
doi:10.1093/gerona/glv175 
49. Lou Y, Wang Z, Xu Y, Zhou P, Cao J, Li Y, et  al. Resveratrol prevents 
doxorubicin-induced cardiotoxicity in H9c2 cells through the inhibition of 
endoplasmic reticulum stress and the activation of the Sirt1 pathway. Int J Mol 
Med (2015) 36:873–80. doi:10.3892/ijmm.2015.2291 
50. Shi Q, Geldenhuys W, Sutariya V, Bishayee A, Patel I, Bhatia D. CArG-driven 
GADD45α activated by resveratrol inhibits lung cancer cells. Genes Cancer 
(2015) 6:220–30. 
51. Yang Z, Yang S, Misner BJ, Chiu R, Liu F, Meyskens FL. Nitric oxide initiates 
progression of human melanoma via a feedback loop mediated by apurinic/
apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. 
Mol Cancer Ther (2008) 7:3751–60. doi:10.1158/1535-7163.MCT-08-0562 
52. Li W, Ma J, Ma Q, Li B, Han L, Liu J, et al. Resveratrol inhibits the epitheli-
al-mesenchymal transition of pancreatic cancer cells via suppression of the 
PI-3K/Akt/NF-κB pathway. Curr Med Chem (2013) 20:4185–94. doi:10.2174
/09298673113209990251 
53. Zhong L-X, Li H, Wu M-L, Liu X-Y, Zhong M-J, Chen X-Y, et al. Inhibition of 
STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian 
cancer cells. J Ovarian Res (2015) 8:25. doi:10.1186/s13048-015-0152-4 
54. Mikuła-Pietrasik J, Sosińska P, Ksiażek K. Resveratrol inhibits ovarian cancer 
cell adhesion to peritoneal mesothelium in vitro by modulating the produc-
tion of α5β1 integrins and hyaluronic acid. Gynecol Oncol (2014) 134:624–30. 
doi:10.1016/j.ygyno.2014.06.022 
55. Gao Q, Yuan Y, Gan H-Z, Peng Q. Resveratrol inhibits the hedgehog signaling 
pathway and epithelial-mesenchymal transition and suppresses gastric 
cancer invasion and metastasis. Oncol Lett (2015) 9:2381–7. doi:10.3892/ 
ol.2015.2988 
56. Qin Y, Ma Z, Dang X, Li W, Ma Q. Effect of resveratrol on proliferation and 
apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhi-
bition of the hedgehog signaling pathway. Mol Med Rep (2014) 10:2563–7. 
doi:10.3892/mmr.2014.2511 
15
Varoni et al. Anticancer Activity of Resveratrol
Frontiers in Nutrition | www.frontiersin.org April 2016 | Volume 3 | Article 8
57. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C, et al. 
Results of a phase I pilot clinical trial examining the effect of plant-derived 
resveratrol and grape powder on Wnt pathway target gene expression in 
colonic mucosa and colon cancer. Cancer Manag Res (2009) 1:25–37. 
58. Zhang P, Li H, Yang B, Yang F, Zhang L-L, Kong Q-Y, et al. Biological signif-
icance and therapeutic implication of resveratrol-inhibited Wnt, Notch and 
STAT3 signaling in cervical cancer cells. Genes Cancer (2014) 5:154–64. 
59. Lin H, Xiong W, Zhang X, Liu B, Zhang W, Zhang Y, et  al. Notch-1 
activation-dependent p53 restoration contributes to resveratrol-induced 
apoptosis in glioblastoma cells. Oncol Rep (2011) 26:925–30. doi:10.3892/or. 
2011.1380 
60. Ji Q, Liu X, Han Z, Zhou L, Sui H, Yan L, et al. Resveratrol suppresses epithe-
lial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads 
signaling pathway mediated Snail/E-cadherin expression. BMC Cancer (2015) 
15:97. doi:10.1186/s12885-015-1119-y 
61. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of 
TRAIL-resistant LNCaP cells by resveratrol (3, 4’, 5 tri-hydroxystilbene): 
molecular mechanisms and therapeutic potential. J Mol Signal (2007) 2:7. 
doi:10.1186/1750-2187-2-7 
62. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol 
(3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apopto-
sis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol 
Cell Biochem (2007) 304:273–85. doi:10.1007/s11010-007-9510-x 
63. Harati K, Slodnik P, Chromik AM, Goertz O, Hirsch T, Kapalschinski N, et al. 
Resveratrol induces apoptosis and alters gene expression in human fibrosar-
coma cells. Anticancer Res (2015) 35:767–74. 
64. Ma L, Li W, Wang R, Nan Y, Wang Q, Liu W, et al. Resveratrol enhanced anti-
cancer effects of cisplatin on non-small cell lung cancer cell lines by inducing 
mitochondrial dysfunction and cell apoptosis. Int J Oncol (2015) 47:1460–8. 
doi:10.3892/ijo.2015.3124 
65. Cai Y, Zhao L, Qin Y, Zhang M, He Y. Resveratrol inhibits proliferation and 
induces apoptosis of nasopharyngeal carcinoma cell line C666-1 through 
AMPK activation. Pharmazie (2015) 70:399–403. 
66. Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee 
A, et  al. A multi-targeted approach to suppress tumor-promoting inflam-
mation. Semin Cancer Biol (2015) 35(Suppl):S151–84. doi:10.1016/j.
semcancer.2015.03.006 
67. Latruffe N, Lançon A, Frazzi R, Aires V, Delmas D, Michaille J-J, et  al. 
Exploring new ways of regulation by resveratrol involving miRNAs, 
with emphasis on inflammation. Ann N Y Acad Sci (2015) 1348:97–106. 
doi:10.1111/nyas.12819 
68. Inoue H, Nakata R. Resveratrol targets in inflammation. Endocr Metab 
Immune Disord Drug Targets (2015) 15:186–95. doi:10.2174/187153031566
6150316120316 
69. Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and 
disease. Anti-inflammatory approaches for colorectal cancer chemopreven-
tion. Am J Physiol Gastrointest Liver Physiol (2015) 309:G59–70. doi:10.1152/
ajpgi.00101.2014 
70. Chin Y-T, Yang S-H, Chang T-C, Changou CA, Lai H-Y, Fu E, et al. Mechanisms 
of dihydrotestosterone action on resveratrol-induced anti-proliferation in 
breast cancer cells with different ERα status. Oncotarget (2015) 6:35866–79. 
doi:10.18632/oncotarget.5482 
71. Jeong SK, Yang K, Park YS, Choi YJ, Oh SJ, Lee CW, et al. Interferon gamma 
induced by resveratrol analog, HS-1793, reverses the properties of tumor asso-
ciated macrophages. Int Immunopharmacol (2014) 22:303–10. doi:10.1016/j.
intimp.2014.07.004 
72. Ruotolo R, Calani L, Fietta E, Brighenti F, Crozier A, Meda C, et  al. Anti-
estrogenic activity of a human resveratrol metabolite. Nutr Metab Cardiovasc 
Dis (2013) 23:1086–92. doi:10.1016/j.numecd.2013.01.002 
73. Zhang S, Cao HJ, Davis FB, Tang H-Y, Davis PJ, Lin H-Y. Oestrogen inhibits 
resveratrol-induced post-translational modification of p53 and apoptosis in 
breast cancer cells. Br J Cancer (2004) 91:178–85. doi:10.1038/sj.bjc.6601902 
74. Kjaer TN, Ornstrup MJ, Poulsen MM, Jørgensen JOL, Hougaard DM, Cohen 
AS, et  al. Resveratrol reduces the levels of circulating androgen precursors 
but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate 
volume. A 4-month randomised trial in middle-aged men. Prostate (2015) 
75:1255–63. doi:10.1002/pros.23006 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Varoni, Lo Faro, Sharifi-Rad and Iriti. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
